{"organizations": [], "uuid": "d397b005144ab9d0af89ee6cf2c33036b5035615", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180416.html", "section_title": "Archive News &amp; Video for Monday, 16 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-navidea-signs-deal-to-sublicense-n/brief-navidea-signs-deal-to-sublicense-nav4694-worldwide-development-rights-idUSFWN1RT09X", "country": "US", "domain_rank": 408, "title": "BRIEF-Navidea Signs Deal To Sublicense Nav4694 Worldwide Development Rights", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.06, "site_type": "news", "published": "2018-04-16T19:11:00.000+03:00", "replies_count": 0, "uuid": "d397b005144ab9d0af89ee6cf2c33036b5035615"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-navidea-signs-deal-to-sublicense-n/brief-navidea-signs-deal-to-sublicense-nav4694-worldwide-development-rights-idUSFWN1RT09X", "ord_in_thread": 0, "title": "BRIEF-Navidea Signs Deal To Sublicense Nav4694 Worldwide Development Rights", "locations": [], "entities": {"persons": [], "locations": [{"name": "beijing", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "navidea biopharmaceuticals inc", "sentiment": "negative"}, {"name": "navidea biopharmaceuticals", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - Navidea Biopharmaceuticals Inc :\n* NAVIDEA SIGNS DEAL TO SUBLICENSE NAV4694 WORLDWIDE DEVELOPMENT RIGHTS\n* NAVIDEA BIOPHARMACEUTICALS INC - ANNOUNCED IT HAS SIGNED A DEAL TO PROVIDE MEILLEUR TECHNOLOGIES WORLDWIDE RIGHTS TO CONDUCT RESEARCH USING NAV4694\n* NAVIDEA BIOPHARMACEUTICALS - AS A RESULT OF AGREEMENT, LITIGATION INITIATED BY BEIJING SINOTAU MEDICAL RESEARCH CO., LTD WILL BE DISMISSED Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-16T19:11:00.000+03:00", "crawled": "2018-04-17T12:14:35.012+03:00", "highlightTitle": ""}